Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT MARKET RELEASE

13 September 2023

CHANGE OF REGISTRY ADDRESS NOTIFICATION

Perth, Western Australia - Australian medical device, digital health technology company, Artrya Limited (ASX: AYA) (Artrya or the Company) advises that in accordance with ASX Listing Rule 3.15.1 and with effect from commencement of business on Monday, 18 September 2023, the Perth office of Computershare Investor Services Pty Limited is moving to:

Level 17 221 St Georges Terrace Perth WA 6000

Telephone numbers and postal address remain unchanged.

Lodgement of documentation by member organisations, securityholders and other parties must be made at the new address from Monday, 18 September 2023.

Artrya Limited Kevin Hart Company Secretary

This announcement was approved by the CEO.

For further information please contact:

Investor Enquiries: Mathew Regan Artrya Limited +61 427 477 298 investors@artrya.com

About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered. Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information, see <u>www.artrya.com</u>

Artrya Limited

ACN 624 005 741 1257 Hay Street, West Perth WA 6005 PO Box 567, West Perth WA 6872 **www.artrya.com** T: 461 8 6478 7816